New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: Identification of ethyl 3-[N-[4-[4- [amino[(ethoxycarbonyl)imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1- [(ethoxycarbonyl)methyl]piperid-4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent

Journal of Medicinal Chemistry

Volumn 40, Issue 21, 1997, Pages 3393-3401

  Badorc, Alain ^a   Bordes, Marie Françoise ^a   De Cointet, Paul ^a   Savi, Pierre ^a   Bernat, André ^a   Lalé, Alain ^a   Petitou, Maurice ^a   Maffrand, Jean Pierre ^a   Herbert, Jean Marc ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; 3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 3 [N [4 [4 (AMINOIMINOMETHYL)PHENYL] 1,3 THIAZOL 2 YL] N [1 (CARBOXYMETHYL)PIPERID 4 YL]AMINO]PROPIONIC ACID; 3 [N [4 [4 [AMINO[(ETHOXYCARBONYL)IMINO]METHYL]PHENYL] 1,3 THIAZOL 2 YL] N [1 [(ETHOXYCARBONYL)METHYL]PIPERID 4 YL]AMINO]PROPIONIC ACID ETHYL ESTER; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BENZYLAMINES; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR STRUCTURE; PAPIO; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; THIAZOLES;

EID: 0030882379     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970240y     Document Type: Article

References (24)

1. Peerschke, E. I.; Zucker, M. B.; Grant, R. A.; Egan, J. J.; Johnson, M. M. Correlation between Fibrinogen Binding to Human Platelet and Platelet Aggregability. Blood 1980, 55, 841-847.
2. Plow, E. F.; Ginsberg, M. H.; Marguerie, G. A. Expression and Function of Adhesive Protein on the Platelet Surface. In Biochemistry of platelets. Phillip, D. R., Shuman, M. R., Eds.; Academic Press: New York, 1986; pp 226-251.
3. Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. Blood 1988, 71, 831-843.
4. Plow, E. F.; Pierschbacher, M. D.; Ruoslahti, E.; Marguerie, G.; Ginsberg, M. H. Arginyl-Glycyl-Aspartic Acid Sequences and Fibrinogen Binding to Platelets. Blood 1987, 70, 110-115.
5. Lefkovits, J.; Plow, E. F.; Topol, E. J. Platelet Glycoprotein IIb/ IIIa Receptors in Cardiovascular Medicine. N. Engl. J. Med. 1995, 332, 1553-1559.
6. Robinson, C. Abciximab. Drugs Future 1995, 20, 457-463.
7. Cadroy, Y.; Houghten, R. A.; Hanson, S. R. RGDV Peptide Selectively Inhibits Platelet-Dependent Thrombus Formation in Vivo. Studies using a baboon model. J. Clin. Invest. 1989, 84, 939-944.
8. Nicholson, N. S.; Panzer-Knodle, S. G.; Salyers, A. K.; et al. Antiplatelet and Antithrombotic Effects of Platelet Glycoprotein IIb/IIIa (GP IIb/IIIa) Inhibition by Arginine-Glycine-Aspartic Acid-Serine (RGDS) and Arginine-Glycine-Aspartic Acid(O-Me)-tyrosine (SC-46749). J. Pharmacol. Exp. Ther. 1989, 256, 876-882.
9. Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Shashidhar, A. R.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M.V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. J. Med. Chem. 1995, 38, 2378-2394.
10. Gould, R. J.; Barrett, J. S.; Eiss, J. D.; Holahan, M. A.; Stranieri, M. T.; Theoharides, A. D.; Lynch, J. J., Jr.; Friedman, P. A.; Duggan, M. E.; Ihle, N. C.; Anderson, P. S.; Hartman, G. D. Characterization of L-703,014, a Novel Fibrinogen Receptor Antagonist, Following Oral Administration to Dogs. Thromb. Haemostas. 1983, 69, a2.
11. Himmelsbach, F.; Austel, V.; Guth, B.; Linz, G.; Muller, T. H.; Pieper, H.; Seewaldt-Becker, E.; Weisenberger, H. Design of Highly Potent Fibrinogen Receptor Antagonists. Eur. J. Med. Chem. 1995, 30, 243s-254s.
12. Pike, N. B.; Foster, M. R.; Hornby, E. J.; Lumley, P. Effect of the Fibrinogen Receptor Antagonist GR144053 Upon Platelet Aggregation ex vivo Following Intravenous and Oral Administration to the Marmoset and Cynomolgus Monkey. Thromb. Haemostas. 1993, 69, a1886.
13. Raddatz, P.; Gante, J. Recent Developments in Glycoprotein IIb/ IIIa Antagonists. Exp. Opin. Ther. Pat. 1995, 5(11), 1163-1183.
14. Peerlinck, K.; De Lepeleire, I.; Goldberg, M.; Farrell, D.; Barrett, J.; Hand, E.; Panebianco, D.; Deckmyn, H.; Vermylen, J.; Arnout, J. MK-383 (L-700,462), a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, Is Active in Man. Circulation 1993, 88 (1), 1512-1517.
15. Theroux, P.; Kouz, S.; Knudtson, M. L.; Kells, C.; Nasmith, J.; Roy, L.; Ave, S. D.; Steiner, B.; Xiao, Z.; Rapold, H. J. A Randomized Double-Blind Controlled Trial with the Non-Peptidic Platelet GPIIb/IIIa Antagonist Ro 44-9883 in Unstable Angina. Circulation 1994, 90, I-232 (abstr).
16. Badorc, A.; Bordes, M. F.; De Cointet, P.; Herbert, J. M.; Maffrand, J. P. FR Patent 015805, December 28, 1994.
17. Metzger, J. V. Thiazoles and their Benzo Derivatives. In Comprehensive Heterocyclic Chemistry, 1st ed.; Potts, K. T., Ed.; Pergamon Press: New York, 1984; Vol. 6, pp 235-331.
18. Kapnang, H.; Charles, G. Reaction des chloroformiates sur les amines tertiaires: Competition entre N-Demethylation, Desamination, N-Debenzylation et N-Desalkylation. (Reactions of chloroformates on tertiary amines: Competition between N-Demethylation, Deamination, N-Debenzylation and N-Dealkylation.) Tetrahedron Lett. 1983, 24, 3233-3236.
19. Olofson, R. A.; Martz, J. T.; Senet, J. P.; Piteau, M.; Malfroot, T. A New Reagent for the Selective, High-Yield N-Dealkylation of Tertiary Amines: Improved Syntheses of Naltrexone and Nalbuphine. J. Org. Chem. 1994, 49, 2081-2082.
20. Neilson, D. G. Imidates including cyclic imidates. In The Chemistry of Amidines and Imidates; Patai, S., Ed.; J. Wiley and Sons: New York, 1975; pp 385-489.
21. Bergmann, E. D.; Ginsburg, D.; Pappo, R. The Michael Reaction. In Organic Reactions; Adams, R., Ed.; J. Wiley and Sons: New York, 1959; Vol. 10, pp 179-560.
22. Foster, M. R.; Hornby, E. J.; Brown, S.; Kitchin, J.; Hann, M.; Ward, P. Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs. Thromb. Res. 1993, 72, 231-245.
23. Born, G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194, 927-929.
24. Ratkovsky, D. A.; Reedy, T. J. Choosing near-linear parameters in the four parameters logistic model for radioligands and related assays. Biometrics 1986, 42, 575-582.